Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 2 for:    GX-H9
Previous Study | Return to List | Next Study

A Clinical Study in AGHD to Assess Safety, Tolerability and Efficacy of GX-H9

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02946606
Recruitment Status : Completed
First Posted : October 27, 2016
Last Update Posted : September 7, 2017
Sponsor:
Information provided by (Responsible Party):
Genexine, Inc.

Brief Summary:
This is a randomized, active-controlled, open-label, sequential dose group, Phase 1b/2 study designed to assess the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of weekly and every other week doses of GX-H9 in the treatment of AGHD.

Condition or disease Intervention/treatment Phase
Adult Growth Hormone Deficiency Drug: GX-H9 Drug: Genotropin Phase 2

Detailed Description:
The subjects who are adequately eligible to attend this clinical trial via screening will be sequentially assigned starting with Group 1. Each group will be comprised of subjects who will receive both GX-H9 and Genotropin, and subjects will be randomly assigned to either GX-H9 and Genotropin in the ratio of 4:1. The treatment will proceed as the proposed group order (Group 1, Group 2, Group 3), and safety and insulin-like growth factor (IGF-1) will be reviewed six weeks after each treatment by the safety monitoring committees before proceeding to the next group.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 45 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Masking Description: Open Label
Primary Purpose: Treatment
Official Title: A Randomized, Active-controlled, Multiple-dose, Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of the Long-acting Antibody-fused Recombinant Human Growth Hormone (GX-H9) in Adult Growth Hormone Deficiency (AGHD)
Study Start Date : January 2015
Actual Primary Completion Date : December 30, 2016
Actual Study Completion Date : December 30, 2016


Arm Intervention/treatment
Experimental: Group 1: GX-H9 + Genotropin
GX-H9 (weekly dose), Genotropin (daily)
Drug: GX-H9
Human growth hormone

Drug: Genotropin
Human growth hormone

Experimental: Group 2: GX-H9 + Genotropin
GX-H9 (weekly dose), Genotropin (daily)
Drug: GX-H9
Human growth hormone

Drug: Genotropin
Human growth hormone

Experimental: Group 3: GX-H9 + Genotropin
GX-H9 (weekly dose), Genotropin (daily)
Drug: GX-H9
Human growth hormone

Drug: Genotropin
Human growth hormone




Primary Outcome Measures :
  1. The change in insulin-like growth factor-1 (IGF-1) levels in relation to time and dose strength [ Time Frame: 12 weeks ]

Secondary Outcome Measures :
  1. Pharmacokinetic (PK) profile of GX-H9 in the treatment of AGHD: Area under the curve, AUC0-t [ Time Frame: 12 weeks ]
  2. PK profile of GX-H9 in the treatment of AGHD: Area under the curve, AUC0-inf [ Time Frame: 12 weeks ]
  3. PK profile of GX-H9 in the treatment of AGHD: Area under the curve, AUC0-tau [ Time Frame: 12 weeks ]
  4. PK profile of GX-H9 in the treatment of AGHD: Maximum serum concentration, Cmax [ Time Frame: 12 weeks ]
  5. PK profile of GX-H9 in the treatment of AGHD: The time taken to reach the maximum concentration, Tmax [ Time Frame: 12 weeks ]
  6. PK profile of GX-H9 in the treatment of AGHD: Half-life, t1/2 [ Time Frame: 12 weeks ]
  7. Pharmacodynamic (PD) profile of GX-H9 in the treatment of AGHD: Maximum serum concentration of IGF-1, Cmax [ Time Frame: 12 weeks ]
  8. PD profile of GX-H9 in the treatment of AGHD: Area under curve of IGF-1, AUC0-t [ Time Frame: 12 weeks ]
  9. PD profile of GX-H9 in the treatment of AGHD: Maximum serum concentration of IGFBP-3, Cmax [ Time Frame: 12 weeks ]
  10. PD profile of GX-H9 in the treatment of AGHD: Area under curve of IGFBP-3, AUC0-t [ Time Frame: 12 weeks ]
  11. Data in Physical examination, Vital signs, Electrocardiography, Clinical Laboratory Test Results Related to Investigational Product [ Time Frame: 12 weeks ]
  12. Immunogenicity Test After subcutaneous injection of GX-H9 [ Time Frame: 12 weeks ]
  13. The changes of glucose metabolism indices [ Time Frame: 12 weeks ]
  14. Data in hormonal status of thyroid, estradiol(female), testosterone(male), and cortisol levels [ Time Frame: 12 weeks ]
  15. The lipid parameters as actual values and percent change from baseline (CFB)at week 12: total cholesterol [ Time Frame: change from baseline at 12weeks ]
  16. The lipid parameters as actual values and percent change from baseline (CFB) at week 12: High-density lipoprotein cholesterol [ Time Frame: change from baseline at 12weeks ]
  17. The lipid parameters as actual values and percent change from baseline (CFB) at week 12: low-density lipoprotein cholesterol [ Time Frame: change from baseline at 12weeks ]
  18. The lipid parameters as actual values and percent change from baseline (CFB) at week 12: Triglycerides [ Time Frame: change from baseline at 12weeks ]
  19. The lipid parameters as actual values and percent change from baseline (CFB) at week 12: lipoprotein[a] [ Time Frame: change from baseline at 12weeks ]
  20. The waist circumference as actual values and CFB at week 12 [ Time Frame: change from baseline at 12weeks ]
  21. The hip circumference as actual values and CFB at week 12 [ Time Frame: change from baseline at 12weeks ]
  22. The waist-to-hip ratio as actual values and CFB at week 12 [ Time Frame: change from baseline at 12weeks ]
  23. The BMI as actual values and CFB at week 12 [ Time Frame: change from baseline at 12weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Each subject must meet all of the following criteria to be enrolled in this study:

  1. Is a male or female aged ≥20 and 65 years with AGHD, either adult onset GHD due to hypothalamic pituitary disease or childhood onset GHD that is either idiopathic or due to hypothalamic pituitary disease or due to genetic causes.
  2. Has documented confirmation (medical history) of GH deficiency during adulthood by 1 or more growth hormone (GH) stimulation tests, as follows:

    • Insulin tolerance test (peak hGH≤3.0 ng/mL)
    • Arginine + growth-hormone-releasing hormone (peak hGH≤4.0 ng/mL)
  3. Has been treated with stable hormonal replacement therapies for deficiencies of other hypothalamo pituitary axes and must have been on an optimized and stable treatment regimen for at least 3 months before screening (free thyroxine [T4] level within normal range at screening). Temporary adjustment of glucocorticoid replacement therapy, as appropriate, is acceptable.
  4. Has a screening IGF-1 level of at least 1 standard deviation (SD) score (IGF-1 SD score <1) below the mean IGF-1 level standardized for age and gender according to the central laboratory reference values.
  5. Has a BMI of ≥18.0 and 35.0 kg/m2 (both male and female subjects).
  6. Has a confirmed negative test result for anti-recombinant human growth hormone (anti-rhGH) antibodies at screening.
  7. Must agree to use appropriate contraceptive methods (ie, condoms, cervical cap in conjunction with spermicide, sterilization, and intra uterine device) during the study and for 6 months after the last dose of study drug.
  8. Female subjects must have a negative serum pregnancy test result at screening.
  9. Must be willing and able to provide written informed consent before performing any study procedures.

Exclusion Criteria:

A subject meeting any of the following criteria will be excluded from the study:

  1. Has evidence of growth of pituitary adenoma or other intracranial tumor within the last 12 months which has to be confirmed by computed tomography or magnetic resonance imaging scan (with contrast) within 3 months before screening. (Subjects with inactive remnant intracranial tumors are eligible).
  2. Is currently receiving antitumor therapy and has a history of malignancy other than i) cranial tumor or leukemia causing GHD, or ii) fully treated basal cell carcinoma or evidence of active malignancy.
  3. Has any clinically significant electrocardiogram (ECG) abnormality at screening.
  4. Has evidence of intracranial hypertension at screening.
  5. Has uncontrolled diabetes mellitus with diet and exercise, as determined based on glycated hemoglobin (HbA1c) levels ≥7.0% at screening.
  6. Has impaired liver function defined as elevation of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 2.0 × upper limit of normal (ULN).
  7. Has impaired kidney function defined as increased serum creatinine levels greater than 1.5 × ULN.
  8. Has had active acromegaly within 18 months before screening.
  9. Has active carpal tunnel syndrome.
  10. Has Prader-Willi syndrome.
  11. Has had active Cushing syndrome within 12 months before screening.
  12. Has any other major medical conditions, including eg, clinically manifested hypertension, tuberculosis, major surgery within the 3 months before screening, or significantly abnormal laboratory test results (eg, disturbed calcium homeostasis); or any other conditions (eg, acute infections) that may influence drug absorption, metabolism, or excretion, or that may interfere with any study variables in the judgment of the investigator.
  13. Has been treated with systemic corticosteroids other than replacement therapy within 3 months before screening.
  14. Is a female subject of childbearing potential who is pregnant, breastfeeding, or intends to become pregnant.
  15. Has been treated with anabolic steroids other than gonadal steroid replacement therapy within 2 months before screening. Oral estrogen replacement and hormonal contraceptives are not allowed in female subjects. For replacement purposes, transdermal estrogens are permitted in female subjects.
  16. Has a history of noncompliance with medications, uncooperativeness, or alcohol/drug abuse.
  17. Has a positive result from serology examination for hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV).
  18. Has a known or suspected hypersensitivity to rhGH.
  19. Has donated blood or had any major blood loss greater than 500 mL within 90 days before screening.
  20. Has a history of any medical or psychiatric condition that in the opinion of the investigator would pose a risk for participation in this study or interfere with the compliance needed for this study.
  21. Has received an investigational drug or product or has participated in a drug study within 60 days before screening.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02946606


Locations
Layout table for location information
Korea, Republic of
Severance Hospital
Seoul, Korea, Republic of
Sponsors and Collaborators
Genexine, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Eun Jig Lee, MD, PhD Yonsei University

Layout table for additonal information
Responsible Party: Genexine, Inc.
ClinicalTrials.gov Identifier: NCT02946606     History of Changes
Other Study ID Numbers: GX-H9-002
First Posted: October 27, 2016    Key Record Dates
Last Update Posted: September 7, 2017
Last Verified: September 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Dwarfism, Pituitary
Endocrine System Diseases
Dwarfism
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases
Bone Diseases, Endocrine
Hypopituitarism
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs